Tesofensine
Triple Monoamine Reuptake Inhibitor
Tesofensine is a triple monoamine reuptake inhibitor — blocking reuptake of dopamine, serotonin, and norepinephrine simultaneously. Originally developed for Parkinson's and Alzheimer's, unexpected weight loss in trial participants redirected its research toward obesity, where Phase 2 data showed weight reductions rivaling early GLP-1 agents.
At a Glance
Its CNS mechanism is fundamentally different from GLP-1 agonists. Rather than acting on gut hormones or peripheral metabolism, tesofensine modulates the central reward and satiety circuitry through monoamine signaling — suppressing appetite via the same neurotransmitter systems that govern hunger, motivation, and energy expenditure.
Phase 2b data published in The Lancet (2008) showed 10.6% weight reduction at 0.5mg and 12.8% at 1mg over 24 weeks versus 2.2% placebo — among the highest CNS-mediated weight loss figures at the time.
Its stimulant profile (increased heart rate and blood pressure at higher doses) has been the primary regulatory obstacle — a tradeoff between efficacy and cardiovascular safety that continues to shape its research position.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
Dopamine Reuptake Inhibition
Blocks dopamine reuptake in reward circuitry, reducing food reward motivation and potentially addressing the hedonic component of overeating.
Serotonin Reuptake Inhibition
Serotonin reuptake blockade enhances satiety signaling through hypothalamic 5-HT receptors — overlapping with the mechanism of older weight loss agents like sibutramine.
Norepinephrine Reuptake Inhibition
NE reuptake blocker increases sympathetic tone, elevating metabolic rate and thermogenesis — adding an energy expenditure component to appetite suppression.
Thermogenic Effect
Triple monoamine elevation increases metabolic rate beyond appetite suppression alone — contributing to a larger caloric deficit than satiety alone.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Obesity weight loss — Phase 2b: 10.6–12.8% body weight reduction over 24 weeks
- CNS appetite regulation research — triple monoamine mechanism vs GLP-1 peripheral approach
- Food reward and hedonic eating models — dopamine pathway in obesity
- Metabolic rate enhancement — thermogenic component of weight loss research
- Parkinson's and Alzheimer's — original research indication before weight loss observations
- Combination with GLP-1 agonists — central + peripheral dual mechanism research
- Cardiovascular safety in CNS-acting weight loss agents — dose-dependent heart rate effects
Tesofensine's central monoamine mechanism positions it as the primary CNS-acting alternative to GLP-1 agonists in obesity research — a different tool for a different mechanistic question.
Tesofensine, semaglutide, and phentermine represent three distinct mechanisms of pharmacological weight loss — peripheral incretin, central monoamine, and sympathomimetic.
| Aspect | Tesofensine | Semaglutide | Phentermine (reference) |
|---|---|---|---|
| Mechanism | Triple monoamine reuptake inhibitor | GLP-1 receptor agonist | Norepinephrine releaser |
| Site of Action | CNS (central) | Peripheral + central | CNS (sympathomimetic) |
| Weight Loss (24wk) | 10.6–12.8% | ~10% (at 1mg) | ~5–8% |
| Cardiovascular | ↑HR and BP (dose-dependent) | Neutral to beneficial | ↑HR and BP |
| Regulatory Status | Phase 2 / not approved | FDA approved | FDA approved (short-term) |
The following reflects findings from published preclinical and clinical safety assessments where available.
Substantial Phase 2 weight loss data — 10–13% over 24 weeks from purely CNS mechanism
Oral bioavailability — once daily tablet, no injection required
Unique CNS mechanism — different target from GLP-1 agonists, useful for mechanistic comparison studies
Cardiovascular effects at higher doses — heart rate and blood pressure elevation the primary regulatory concern; dose-dependent
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026